Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72501 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, online erschienen am 11.11.2026. Verfasst von Dary Phen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Melanoma, Head and Neck Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined. We evaluated real‐world outcomes after curative‐intent surgery and the association of adjuvant immune checkpoint inhibitor (ICI) therapy with survival.
Methods
We retrospectively identified patients with HNMM who underwent curative‐intent surgery from 1990 to 2024. Overall survival (OS) and progression‐free survival (PFS) were estimated from surgery using Kaplan–Meier methods. Univariable Cox models evaluated associations of adjuvant ICI with survival.
Results
Among 89 patients, median follow‐up was 38 months (IQR, 18–60). Most tumors arose in the nasal cavity or paranasal sinuses (72/89, 81%); 23 (26%) had T4 disease and 7 (8%) had regional nodal metastases. Among tested patients, BRAF, NRAS, and KIT alterations were identified in 4/37 (11%), 7/25 (28%), and 0/28 (0%), respectively. Median tumor mutational burden was 3.45 mutations/Mb (IQR, 2.15–7.95; n = 10) and median PD‐L1 tumor proportion score was 0.5% (IQR, 0%–1%; n = 6). Seventeen patients (19%) received adjuvant ICI, including anti–PD‐1 monotherapy ( n = 10), CTLA‐4 monotherapy ( n = 1), or combination anti–PD‐1/CTLA‐4 therapy ( n = 6); 48 (54%) received adjuvant radiotherapy. Two‐ and 5‐year OS were 66% and 46%, respectively; corresponding PFS estimates were 65% and 46%. Adjuvant ICI was not associated with improved OS (hazard ratio [HR], 0.69; 95% CI, 0.31–1.55; p = 0.37) or PFS (HR, 1.06; 95% CI, 0.50–2.21; p = 0.88). Initial progression patterns were broadly similar between groups.
Conclusions
In this single‐institution cohort of surgically treated HNMM, adjuvant ICI was not associated with improved OS or PFS. Patterns of initial disease progression were similar between treatment groups, underscoring the need for more effective peri‐operative strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California, San Francisco, California, USA.
- Department of Radiation Oncology, University of California, San Francisco, California, USA.
- Department of Otolaryngology, Head and Neck Surgery, University of California, San Francisco, California, USA.
ORCID-Profile: Dary Phen, Justin Fortino, Ivan El-Sayed, Derrick Tao, Katy K Tsai, Adil I Daud, Jason W Chan
Zitieren
APA
Phen, D., Fortino, J., El-Sayed, I., Lee, J. C., Cho, N. W., Amouzegar, A., Tao, D., Tsai, K. K., Daud, A. I., & Chan, J. W. (2026). Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72501
Vancouver
Phen D, Fortino J, El-Sayed I, Lee JC, Cho NW, Amouzegar A, et al. Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72501
BibTeX
@article{Phen2026,
author = {Phen, Dary and Fortino, Justin and El-Sayed, Ivan and Lee, James C and Cho, Nam Woo and Amouzegar, Afsaneh and Tao, Derrick and Tsai, Katy K and Daud, Adil I and Chan, Jason W},
title = {Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72501}
}
EUVIMED